DBV Technologies | DBVT - Sales Revenues


DBV Technologies reported $2.77M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
BioMarin Pharmaceutical USD 766M 109M Mar/2026
DBV Technologies USD 2.77M 1.31M Sep/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026